Déciga-Campos Myrna, López Uriah Guevara, Reval Maria Irene Díaz, López-Muñoz Francisco J
Departamento de Farmacobiología, Lab. No. 7 Dolor y Analgesia, CINVESTAV-IPN, Calz. de los Tenorios No. 235, Col. Granjas Coapa, Deleg. Tlálpan, C.P. 14330 México D.F., México.
Eur J Pharmacol. 2003 Jan 24;460(2-3):99-107. doi: 10.1016/s0014-2999(02)02920-5.
Synergism has been used to obtain analgesia at doses at which side effects are minimal. In addition, it has been demonstrated that inhibition of cyclooxygenase-2 is responsible for the therapeutic effects of nonsteroidal anti-inflammatory drugs (NSAIDs). The aim of this study was to evaluate the antinociceptive interaction between the preferential COX-2 inhibitor, rofecoxib and morphine. Several combinations were evaluated using the pain-induced functional impairment model (PIFIR), a rat model of arthritic pain. Surface of synergistic interaction (SSI) analysis and an isobolographic method were used to detect the antinociceptive potency of the drugs, given either individually or in combination. The surface of synergistic interaction was calculated from the total antinociceptive effect produced by the combination after subtraction of the antinociceptive effect produced by each individual drug. Male rats received orally morphine alone (10, 17.8, 31.6, 56.2 and 100.0 mg/kg), rofecoxib alone (3.2, 5.6, 10, 31.6, 56.2 and 74.0 mg/kg) or 12 different combinations of morphine and rofecoxib. Three combinations exhibited potentiation of antinociceptive effects (10 mg/kg of morphine with either 5.6, 10 or 31.6 mg/kg of rofecoxib), whereas the other nine combinations showed additive antinociceptive effects. The combination of morphine, 56.2 mg/kg (p.o.), and rofecoxib, 31.6 mg/kg (p.o.), produced the maximum antinociceptive effect (P<0.05). This combination caused gastric injuries less severe than those observed with indomethacin, i.e. it reduced ulcers and erosion formation. The synergistic antinociceptive effects of rofecoxib and morphine are important and suggest that combinations with drugs may decrease the side effects associated with the use of nonselective NSAIDs. Furthermore, the present results suggest that combinations containing opioid drugs and selective COX-2 inhibitors may have clinical utility in pain therapy.
协同作用已被用于在副作用最小的剂量下获得镇痛效果。此外,已有研究表明,环氧化酶-2的抑制作用是非甾体抗炎药(NSAIDs)治疗效果的原因。本研究的目的是评估选择性COX-2抑制剂罗非昔布与吗啡之间的抗伤害感受相互作用。使用疼痛诱导功能障碍模型(PIFIR),一种关节炎疼痛的大鼠模型,评估了几种组合。采用协同作用表面(SSI)分析和等效应线图法来检测单独给药或联合给药时药物的抗伤害感受效力。协同作用表面是通过从组合产生的总抗伤害感受效应中减去每种单独药物产生的抗伤害感受效应来计算的。雄性大鼠口服单独的吗啡(10、17.8、31.6、56.2和100.0mg/kg)、单独的罗非昔布(3.2、5.6、10、31.6、56.2和74.0mg/kg)或吗啡与罗非昔布的12种不同组合。三种组合表现出抗伤害感受作用增强(10mg/kg吗啡与5.6、10或31.6mg/kg罗非昔布);而其他九种组合表现出相加的抗伤害感受作用。吗啡56.2mg/kg(口服)与罗非昔布31.6mg/kg(口服)的组合产生了最大的抗伤害感受作用(P<0.05)。这种组合引起的胃损伤比吲哚美辛引起的损伤轻,即它减少了溃疡和糜烂的形成。罗非昔布和吗啡的协同抗伤害感受作用很重要,表明与药物联合使用可能会减少与使用非选择性NSAIDs相关的副作用。此外,目前的结果表明,含有阿片类药物和选择性COX-2抑制剂的组合在疼痛治疗中可能具有临床应用价值。